Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Castle Creek Biosciences

Status and phase: Enrolling; Phase 3

Conditions: Dystrophic Epidermolysis Bullosa

Treatments: Biological: D-Fi

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06892639

CCB-EB-304

Details and patient eligibility

About

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Full description

CCB-EB-304 is a multi-center, intra-patient randomized and controlled, open-label, rater-blinded Phase 3 study of D-Fi for the treatment of persistent non-healing and recurrent DEB wounds in approximately 32 subjects. Each subject will serve as his/her own control. Each subject's target wounds will be paired then randomized to receive D-Fi (treatment wound) or remain untreated (control wound). One target wound pair will be identified for each subject.

Subjects will receive intradermal injections of D-Fi in each specified treatment wound in three or more treatment sessions. The first treatment session occurs at Day 1, the second at Week 8/Month 2 and the third at Week 16/Month 4. Additional treatment sessions may occur at Week 26/Month 6 and Week 32/Month 8 and Week 40/Month 10 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated. Safety and efficacy assessments will occur at scheduled intervals through Week 48/Month 12, when the treatment period is completed, and a long-term safety follow-up period (through 15 years) commences for subjects who have received one or more D-Fi injections.

Enrollment: 32 estimated patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female ≥2 years of age at the Screening visit
• Clinical diagnosis of DEB with confirmation of COL7A1 genetic mutation.

Exclusion criteria

• Medical instability limiting ability to travel to the investigative site.
• Active infection with human immunodeficiency virus, hepatitis B or hepatitis C.
• The presence of COL7 antibodies.
• Evidence of systemic infection.
• Known allergy to any of the constituents of the product.
• Female who is pregnant or breastfeeding.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

32 participants in 1 patient group

D-Fi COL7A1 Genetically-Corrected Autologous Fibroblasts

Experimental group

Description:

Intra-subject randomized (paired wounds in each subject receive experimental treatment, D-Fi, or remain untreated). One target wound pair will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (D-Fi is administered) or control wound. Subjects will receive intradermal injections of D-Fi in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1, the second at Week 8/Month 2 and the third at Week 16/Month 4. Additional treatment sessions may occur at Week 26/Month 6, Week 32/Month 8 and Week 40/Month 10 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.

Treatment:

Biological: D-Fi